256 related articles for article (PubMed ID: 35920382)
1. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.
Narula N; Wong ECL; Dulai PS; Sengupta NK; Marshall JK; Colombel JF; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1579-1587.e2. PubMed ID: 33838348
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
Narula N; Wong ECL; Dulai PS; Marshall JK; Colombel JF; Reinisch W
J Crohns Colitis; 2021 Oct; 15(10):1649-1657. PubMed ID: 33693522
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
Am J Gastroenterol; 2022 Jul; 117(7):1106-1117. PubMed ID: 35435862
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
Narula N; Wong ECL; Marshall JK; Colombel JF; Dulai PS; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1588-1597.e3. PubMed ID: 34329776
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
[TBL] [Abstract][Full Text] [Related]
9. End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
Wong ECL; Buffone E; Lee SJ; Dulai PS; Marshall JK; Reinisch W; Narula N
J Crohns Colitis; 2021 Jul; 15(7):1114-1119. PubMed ID: 33245751
[TBL] [Abstract][Full Text] [Related]
10. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.
Wong ECL; Merat S; Monaco C; Dulai PS; Jairath V; Marshall JK; Reinisch W; Narula N
Dig Dis Sci; 2023 Jun; 68(6):2635-2646. PubMed ID: 37119375
[TBL] [Abstract][Full Text] [Related]
12. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
[No Abstract] [Full Text] [Related]
13. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
16. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
19. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]